New York, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, ...
Sangamo Therapeutics said today it has treated the first patient in the Phase I/II CHAMPIONS clinical trial assessing its in vivo genome-editing candidate therapy SB-913 for mucopolysaccharidosis type ...
– Additional Posters Underscore Broad Potential of J-Brain Cargo ® Platform, Including Preclinical Data for Pabinafusp Alfa in MPS II and Nonclinical Data for JR-446 in MPS IIIB – "The data presented ...
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II >80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain ...
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured ...
The last time I spoke about REGENXBIO Inc. (NASDAQ:RGNX) it was in a Seeking Alpha article entitled "Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder". Regarding this ...
Denali Therapeutics (($DNLI)) announced an update on their ongoing clinical study. Denali Therapeutics has launched an open-label extension study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback